RÉSUMÉ
BACKGROUND: Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) lower low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia. However, some patients receiving PCSK9i therapy might require additional lipid-lowering therapy (LLT) to reach LDL-C goals. Bempedoic acid is an oral, once-daily, ATP-citrate lyase inhibitor that significantly lowers LDL-C in patients with hypercholesterolemia when given alone or as add-on therapy to statins and/or ezetimibe. OBJECTIVE: Assess safety and efficacy of bempedoic acid added to PCSK9i (evolocumab) background therapy in patients with hypercholesterolemia. METHODS: This phase 2, randomized, double-blind, placebo-controlled study was conducted in three phases: 1.5-month screening/washout period including discontinuation of all LLTs, a 3-month period wherein patients initiated background PCSK9i therapy, and a 2-month treatment period in which patients were randomized 1:1 to receive bempedoic acid 180â¯mg or placebo once daily while continuing PCSK9i therapy. RESULTS: Of 59 patients randomized, 57 completed the study. Mean baseline LDL-C after 3 months of PCSK9i background therapy was 103.1⯱ ±â¯30.4â¯mg/dL. Bempedoic acid added to background PCSK9i therapy significantly lowered LDL-C by 30.3% (P < .001) vs placebo. Compared with placebo, bempedoic acid significantly lowered apolipoprotein B, non-high-density lipoprotein cholesterol, and total cholesterol (nominal P < .001 for all), and high-sensitivity C-reactive protein (P = .029). When added to background PCSK9i therapy, the safety profile of bempedoic acid was comparable to that observed for placebo. CONCLUSIONS: When added to a background of PCSK9i therapy, bempedoic acid significantly lowered LDL-C levels with a safety profile comparable to placebo in patients with hypercholesterolemia.
Sujet(s)
Diacides carboxyliques/administration et posologie , Acides gras/administration et posologie , Hypercholestérolémie/sang , Hypercholestérolémie/traitement médicamenteux , Hypolipémiants/administration et posologie , Inhibiteurs de PCSK9/administration et posologie , Proprotéine convertase 9/sang , Sujet âgé , Cholestérol LDL/antagonistes et inhibiteurs , Cholestérol LDL/sang , Méthode en double aveugle , Association de médicaments , Femelle , Humains , Mâle , Adulte d'âge moyenRÉSUMÉ
The unsymmetrical Mn-Anderson polyoxometalate cluster, [N(C4H9)4]3[MnMo6O18(C4H6O3NO2)(C4H6O3NH2)] (1; N(C4H9)4(+) = TBA(+)), has been prepared and characterized by X-ray crystallography and electrospray ionization mass spectrometry (ESI-MS). Covalent functionalization of compound 1 leads to the controlled assemblies of unsymmetrical alkoxopolyoxometalate clusters of compounds 2-5, which can be directly observed in solution as revealed by ESI-MS studies.